RAGE fusion protein - Galactica Pharmaceuticals
Latest Information Update: 24 Jan 2024
At a glance
- Originator Galactica Pharmaceuticals
- Class Antivirals; Recombinant fusion proteins
- Mechanism of Action Receptor for advanced glycation end product expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 05 Jan 2024 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by Galactica Pharmaceuticals
- 11 Oct 2023 Galactica Pharmaceuticals has patent protection for RAGE fusion protein in USA and Europe (and likely Japan) (Galactica Pharmaceuticals website, October 2023).
- 11 Oct 2023 Preclinical trials in COVID-2019 infections in USA (Parenteral) before October 2023